Literature DB >> 25064169

Population pharmacokinetic model to analyze nevirapine multiple-peaks profile after a single oral dose.

Manuel Ibarra1, Marta Vázquez, Pietro Fagiolino.   

Abstract

Nevirapine (NVP) extensive data obtained after oral single dose administration of 200 mg in a crossover study involving 16 healthy subjects was used to develop a descriptive population pharmacokinetic model including drug recirculation, since secondary peaks were observed in plasma concentration-time profiles for all subjects. Through implementation of model event time feature in NONMEM 7.3.0, a simple mechanistic model physiologically consistent with the process of drug cycling was able to describe multiple peaks phenomena and quantify its pharmacokinetic parameters, achieving a better performance than its analogue conventional one. Absorption process, between subject and-between occasion variability of pharmacokinetic parameters was also assessed. Estimated mean fraction of NVP bioavailable dose undergoing recirculation process was 51.6 %, a magnitude which could hardly be explained by enterohepatic cycling. In this work we propose an alternative disposition process to explain NVP drug recirculation: gastric secretion with posterior intestinal reabsorption. Due to physicochemical and pharmacokinetic properties of the drug, this neglected phenomenon is more likely to explain the results obtained, and might be present in disposition of several basic drugs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25064169     DOI: 10.1007/s10928-014-9371-3

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  30 in total

1.  Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers.

Authors:  M J Lamson; J P Sabo; T R MacGregor; J W Pav; L Rowland; A Hawi; M Cappola; P Robinson
Journal:  Biopharm Drug Dispos       Date:  1999-09       Impact factor: 1.627

2.  Disposition and biotransformation of the antiretroviral drug nevirapine in humans.

Authors:  P Riska; M Lamson; T MacGregor; J Sabo; S Hattox; J Pav; J Keirns
Journal:  Drug Metab Dispos       Date:  1999-08       Impact factor: 3.922

3.  Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture.

Authors:  Elke Störmer; Lisa L von Moltke; Michael D Perloff; David J Greenblatt
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

4.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

5.  Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450.

Authors:  D A Erickson; G Mather; W F Trager; R H Levy; J J Keirns
Journal:  Drug Metab Dispos       Date:  1999-12       Impact factor: 3.922

6.  Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma.

Authors:  Andrea Antinori; Carlo Federico Perno; Maria Letizia Giancola; Federica Forbici; Giuseppe Ippolito; Richard M Hoetelmans; Stephen C Piscitelli
Journal:  Clin Infect Dis       Date:  2005-11-10       Impact factor: 9.079

7.  CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans.

Authors:  T Furuta; K Ohashi; K Kosuge; X J Zhao; M Takashima; M Kimura; M Nishimoto; H Hanai; E Kaneko; T Ishizaki
Journal:  Clin Pharmacol Ther       Date:  1999-05       Impact factor: 6.875

8.  Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.

Authors:  Monidarin Chou; Julie Bertrand; Olivier Segeral; Céline Verstuyft; Laurence Borand; Emmanuelle Comets; Clotilde Le Tiec; Laurent Becquemont; Vara Ouk; France Mentre; Anne-Marie Taburet
Journal:  Antimicrob Agents Chemother       Date:  2010-08-09       Impact factor: 5.191

9.  Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state.

Authors:  Patty Fan-Havard; Zhongfa Liu; Monidarin Chou; Yonghua Ling; Aurélie Barrail-Tran; David W Haas; Anne-Marie Taburet
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

10.  Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.

Authors:  Alessandro Schipani; Christoph Wyen; Tabitha Mahungu; Heidy Hendra; Deirdre Egan; Marco Siccardi; Gerry Davies; Saye Khoo; Gerd Fätkenheuer; Michael Youle; Jürgen Rockstroh; Norbert H Brockmeyer; Margaret A Johnson; Andrew Owen; David J Back
Journal:  J Antimicrob Chemother       Date:  2011-03-25       Impact factor: 5.790

View more
  4 in total

1.  Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans.

Authors:  Tae Hwan Kim; Soyoung Shin; Cornelia B Landersdorfer; Yong Ha Chi; Soo Heui Paik; Jayhyuk Myung; Rajbharan Yadav; Stefan Horkovics-Kovats; Jürgen B Bulitta; Beom Soo Shin
Journal:  AAPS J       Date:  2015-05-20       Impact factor: 4.009

2.  A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways.

Authors:  Maïlys De Sousa Mendes; Gabrielle Lui; Yi Zheng; Claire Pressiat; Deborah Hirt; Elodie Valade; Naïm Bouazza; Frantz Foissac; Stephane Blanche; Jean-Marc Treluyer; Saik Urien; Sihem Benaboud
Journal:  Clin Pharmacokinet       Date:  2017-05       Impact factor: 6.447

Review 3.  Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIV.

Authors:  Leena Zino; Jurjen S Kingma; Catia Marzolini; Olivier Richel; David M Burger; Angela Colbers
Journal:  Clin Pharmacokinet       Date:  2022-04-11       Impact factor: 5.577

4.  Enteric reabsorption processes and their impact on drug pharmacokinetics.

Authors:  Manuel Ibarra; Iñaki F Trocóniz; Pietro Fagiolino
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.